Original Research Article

Effect of dexmedetomidine on hemodynamic and recovery responses during tracheal extubation

Shabeel Aboobacker C P1, Shamjith Kunikkakath1,*, Melbin Baby1, Salman Mohammed Kutty C1
1Dept. of Anaesthesia, MES Academy of Medical Sciences, Kolathur, Kerala, India

ARTICLE INFO

Article history:
Received 18-12-2020
Accepted 30-01-2021
Available online 01-06-2021

Keywords:
Dexmedetomidine
Bradycardia
Hemodynamic responses
Tracheal extubation

ABSTRACT

Introduction: Endotracheal extubation is associated with cardiovascular and airway responses leading to tachycardia, hypertension, arrhythmias, myocardial ischemia, coughing, agitation, bronchospasm, increased bleeding, raised intracranial and intraocular pressure which may be life threatening especially in vulnerable patients. Dexmedetomidine, a highly selective α2-adrenergic agonist is found to attenuate these effects and provide a smooth extubation.

Objective: To assess the effect of dexmedetomidine on hemodynamic and ventilatory recovery during tracheal extubation.

Materials and Methods: This comparative study was done in 42 patients who fulfilled the inclusion and exclusion criteria between the age group of 20 to 45 years from both sexes were randomly allocated to two groups of 21 each. One group received 0.5mg Dexmedetomidine and the other group received 100ml NS. Both groups were compared for the hemodynamic parameters at different time intervals during the whole procedure and were compared for differences if any.

Results: In the study group, parameters like Mean arterial pressure, Systolic Blood Pressure, Diastolic Blood Pressure and Heart Rate were under control than the control group. The extubation quality score between controls and dexmedetomidine group (2.14 vs. 1.24) is statistically significant (P<0.001). 14.28% of study group had cough compared to 52.39% in the control group. Bradycardia and Hypertension were significantly higher in the study population.

Conclusion: Just before extubation, administration of dexmedetomidine ensures the smooth extubation of the trachea and reduces the cardiovascular responses. It also provides adequate sedation postoperatively.

© This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/) which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

1. Introduction

During surgery, tracheal intubation is done to maintain a patent airway and to facilitate tracheal suctioning. Weaning of an artificial ventilation after surgery when the need for it no longer exists is known as tracheal extubation. Reflex reactions like tracheal and laryngeal irritation can occur during extubation with mild or no sedation.1 Breath holding, straining, coughing or laryngospasm should not be there during extubation.2 Weaning from anesthesia and ventilatory support can be linked with rise in plasma catecholamines, tachycardia and hypertension causing elevated myocardial contractility and systemic vascular resistance.3

The carbon dioxide insufflations and pneumoperitoneum required in laparoscopic surgeries may lead to an increase in plasma renin activity, adrenaline, nor-adrenaline levels thereby resulting in increase in systemic and pulmonary vascular resistance, hypertension, tachycardia, and a compromised cardiac output. Further the reverse Trendelenburg position during surgery reduces venous return and hence further reduction in cardiac output. These hemodynamic changes predisposes the myocardium to ischemia which might be life threatening in a susceptible
patients at the time of extubation. Several hypotheses have been put forward for the sudden increase in heart rate (HR) and blood pressure (BP) during extubation. Factors during emergence like catecholamine surge, irritation of the airway, post surgery pain can contribute to the changes in vitals. Though temporary and short, these changes are of major concern for an anesthesiologist. The peak changes occur the first minute following extubation and may prolong for about 10 minutes. These changes are tolerated by most of the patients without any serious consequences. Patients suffering from systemic diseases like coronary artery disease, diabetes, hypertension may or may not tolerate these hemodynamic responses.

Numerous drugs are being used to reduce these responses such as intravenous lignocaine, short-acting opioids such as fentanyl and remifentanil, esmolol, labetalol, dexmedetomidine, diltiazem, verapamil, alfentanil, lidocaine, magnesium sulphate, propofol and intratracheal local anesthetic instillation. Dexmedetomidine, a highly selective α2-adrenoreceptor agonist, induces sedation and analgesia without affecting the patients current respiratory condition. It is eight times more potent than clonidine in suppressing catecholamine release in response to stress. Intravenous administration of dexmedetomidine throughout perioperative period has been found to decrease serum catecholamine levels by 90%, thereby reducing the hemodynamic response to laryngoscopy, tracheal intubation, pneumoperitoneum and extubation. It also provides sedation without causing respiratory depression thus minimizing the post-operative analgesic requirements. From the available literature, it is evident that there is a significant reduction in circulating catecholamines, which reduces incidence of hypertension and tachycardia.

Hence this study was initiated to assess the effect of dexmedetomidine on hemodynamic parameters and recovery responses during and after the tracheal extubation.

2. Materials and Methods

This is a prospective comparative study. Institutional Human ethical committee approval was obtained before the start of the study. 42 patients between the age group of 20 to 45 years from both sexes were randomly allocated in to two groups. Inclusion criteria includes, subjects fulfilling the physical status I and II according to American Society of Anesthesiologists (ASA) and those who are scheduled for elective general surgical, urological and gynecological procedures without comorbidities. Exclusion criteria includes patients with severe obesity (body mass index greater than 35), renal insufficiency (serum creatinine more than 1.6 mg/dl), and liver dysfunction (serum glutamic oxaloacetic transaminase/serum glutamic pyruvic transaminase values more than 50% of normal), patients with difficult airways, cardiorespiratory abnormalities (Diabetes, Hypertension, New York Heart Association heart failure grades 3 and 4, obstructive and restrictive lung diseases), and planned / emergency surgeries in neck and oral cavity.

Those patients who fulfilled the inclusion criteria were explained about the rights of the patient, objective of the study and written informed consent was obtained from all the study participants.

Detailed history taking and complete physical examination during pre-anesthetic checkup was done for all the study participants. Routine investigations like complete blood picture, blood urea and serum creatinine, blood grouping/typing, were performed as well.

Before the surgical procedure, patients were kept on NPO (nil per oral) for a duration of 6 hours. All patients were uniformly premeditated with Inj. Glycopyrrolate 0.2mg IM 30 minutes before shifting to operation theatre.

Upon arrival of the patient in the operation theatre, intravenous access with 18 G cannula was inserted. Isoflurane, fentanyl, Propofol, nitrous oxide-oxygen, and vecuronium were the standard anesthesia drugs and techniques used for both the groups. Standard monitoring comprised of non-invasive blood pressure, EtCO2 ECG and pulse oximetry (Spo2).

Subjects were divided into two groups of twenty one each randomly by sealed envelope technique. Subjects in one group received dexmedetomidine 0.5 mcg/kg in 100 ml normal saline (NS) over 15 minutes. The subjects in other group received 100 ml NS only over 15 minutes. This was administered 30 minutes prior to the end of the surgery.

Hemodynamic parameters like heart rate, mean arterial pressure, diastolic Blood Pressure and systolic blood pressure were recorded at the start of intravenous NS or drug injection and thereafter at one, five, ten and fifteen minutes. Intravenous administration of neostigmine 0.05 mg/kg and atropine 0.02 mg/kg reverse the residual neuromuscular blockade. Trachea was extubated once the suction of throat was done and the patient had spontaneous respiration and able to obey simple commands. Anesthesiologist performing tracheal extubation was blinded to the study drugs. Parameters like heart rate, mean arterial pressure, diastolic Blood Pressure and systolic blood pressure were recorded during extubation and thereafter at 1,5,10 and 15 minutes. Adverse effects like bradycardia, hypotension laryngospasm, bronchospasm, vomiting, respiratory depression, desaturation, or undue sedation was treated with utmost care.

Bradycardia was defined as a heart rate of less than 60/min. If bradycardia is associated with hemodynamic instability it must be treated with intravenous atropine (0.6 mg).

Hypotension was defined as a decrease in a mean arterial pressure of less than 60 mmHg or systolic blood pressure...
of more than 30 mmHg from baseline. It was corrected with intravenous fluids and 3 mg of IV mephentermine was given in few required cases.

Quality of extubation was evaluated on a prevalidated and structured five point likert scale based on cough during extubation. Postoperative sedation was assessed using another prevalidated and structured 6 point Ramsay Scale.

The hemodynamic parameters were assessed and recorded in both the groups. Data was entered in Microsoft Excel and analyzed using SPSS (Statistical Package for Social Sciences), version 21. Student T test was used to compare the mean values of different parameters. Fisher exact test was used to assess the hemodynamic responses and adverse events between the groups. P value <0.05 was considered as statistically significant result.

3. Results

The heart rate, SBP, DBP, MAP of dexmedetomidine group was more or less maintained around the normal range while in NS only group there was an increase after 5th minute of stopping the inhalational agent. Further there is a statistically significant increase in these values after extubation in the control group when compared to dexmedetomidine group from the fifth minute of giving the drug till 15 minutes after extubation. (Table 1, Figures 1, 2, 3 and 4)

The mean extubation quality score for NS only group was 2.14 while that of Dexmedetomidine group was 1.24. Around 65.48% of study population were extubated without severe cough. The results are statistically significant. (Table 2)

Time for extubation and eye-opening was prolonged in study group than the controls but it was not statistically significant (2.43 vs 2.19, P>0.05) (Table 2). Majority (61.9%) of those who were on Dexmedetomidine were drowsy compared to 28.57% in control group. And the results were statistically significant (P=0.03).

Elevated blood pressure was seen only in 9.5% of dexmedetomidine group when compared to the control group (81%). Cough was present in 14.28% of dexmedetomidine group and 52.39% of NS only group. Hypotension was not observed in the control group but was present in 19% of study population. Around 9.5% of study group had experienced bradycardia as compared to none in the controls. All these results were statistically significant. Laryngospasm, bronchospasm, desaturation and undue sedation was not found in both the groups. (Table 4)

Comparison of hemodynamic parameters between the groups at various time intervals until 15 min after extubation.

4. Discussion

Exutubation can be associated with coughing and hemodynamic alterations. Strain due to coughing can cause myocardial ischemia, increase in intracranial pressure and intraocular pressure, bronchospasm, tachycardia, hypertension and surgical bleeding. Tracheal extubation may also initiate several respiratory complications (eg, laryngospasm, airway obstruction, desaturation).
Table 1: Comparison of hemodynamic parameters between the groups at various time intervals until 15 min after extubation

| Group          | Heart Rate | SBP | DBP | MAP |
|----------------|------------|-----|-----|-----|
|                | Mean  | SD   | SIG | Mean | SD   | SIG | Mean  | SD   | SIG |
| Baseline       |        |      |     |      |      |     |        |      |     |
| NS Only        | 70.86 | 8.487 | 0.473 | 125.67 | 8.575 | 0.432 | 80.29  | 8.99 | 0.475 |
| Dexmedetomidine| 69    | 8.112 |        | 123.62 | 8.145 |        | 78.29  | 8.995| 0.475 |
| 1<sup>st</sup> min from baseline | NS Only | 69.33 | 8.218 | 0.146 | 126.05 | 6.652 | <0.009 | 80.05 | 8.874 | 0.103 |
| Dexmedetomidine| 65.86 | 6.901 |        | 118.81 | 9.887 |        | 75.57  | 8.506| 0.022 |
| 5<sup>th</sup> min from baseline | NS Only | 68.57 | 7.298 | 0.012 | 126 | 6.253 | <0.001 | 80.1 | 7.155 | 0.012 |
| Dexmedetomidine| 62.9  | 6.602 |        | 114.43 | 9.958 |        | 73.67  | 8.558| 0.001 |
| 10<sup>th</sup> min from baseline | NS Only | 68.43 | 7.639 | 0.001 | 127.1 | 6.024 | <0.001 | 79.86 | 7.793 | 0.005 |
| Dexmedetomidine| 60.86 | 6.703 |        | 112.48 | 9.19 |        | 72.9  | 7.217 | 85.95 | 6.815 |
| 15<sup>th</sup> min from baseline | NS Only | 69.24 | 6.796 | <0.001 | 127.57 | 6.975 | <0.001 | 80.43 | 7.633 | <0.001 |
| Dexmedetomidine| 59.29 | 6.459 |        | 111.24 | 9.354 |        | 70.24  | 7.529 | 83.43 | 7.089 |
| Before Extubation | NS Only | 86.1 | 7.622 | <0.001 | 143.14 | 3.953 | <0.001 | 89.81 | 5.724 | <0.001 |
| Dexmedetomidine| 72.52 | 8.71 |        | 125.57 | 6.516 |        | 78.33  | 9.769 | 107.24 | 4.471 |
| 1<sup>st</sup> min after extubation | NS Only | 86.86 | 7.227 | <0.001 | 144 | 4.254 | <0.001 | 89.95 | 5.181 | <0.001 |
| Dexmedetomidine| 72.71 | 7.584 |        | 123.76 | 7.981 |        | 76.71  | 9.35 | 107.62 | 4.068 |
| 5<sup>th</sup> min after extubation | NS Only | 85.67 | 6.296 | <0.001 | 141.43 | 3.558 | <0.001 | 89.05 | 4.08 | <0.001 |
| Dexmedetomidine| 70.33 | 8.126 |        | 119.95 | 9.479 |        | 75.81  | 8.914 | 106.29 | 3.117 |
| 10<sup>th</sup> min after extubation | NS Only | 83.57 | 6.313 | <0.001 | 138.95 | 3.801 | <0.001 | 87.1 | 4.46 | <0.001 |
| Dexmedetomidine| 68.9 | 8.203 |        | 119.67 | 8.587 |        | 74.38  | 8.352 | 104 | 7.656 |
| 15<sup>th</sup> min after extubation | NS Only | 82.33 | 5.351 | <0.001 | 136.9 | 4.527 | <0.001 | 85.38 | 4.433 | <0.001 |
| Dexmedetomidine| 67.48 | 8.658 |        | 118.9 | 8.82 |        | 72.76  | 8.814 | 102.33 | 3.941 |

Note: NS Only = Normal saline only; Dexmedetomidine = Dexmedetomidine.
Table 2: Comparison of extubation quality score between both groups

| Group         | Mean | Std. Deviation | Mean difference | T Value | P Value |
|---------------|------|----------------|-----------------|---------|---------|
| NS only       | 2.14 | 0.964          |                 |         |         |
| Dexmedetomidine | 1.24 | 0.436          | 0.9             | 3.919   | 0.001   |

Table 3: Comparison of Ramsay score between both groups

| Group         | Mean | Std. Deviation | Mean difference | T Value | P Value |
|---------------|------|----------------|-----------------|---------|---------|
| NS only       | 2.14 | 0.964          | 0.9             | 3.919   | 0.001   |
| Dexmedetomidine | 1.24 | 0.436          |                 |         |         |

Table 4: Comparison of side effects between the dexmedetomidine group and the controls

| S. No | Side effect     | NS only | % | Dexmedetomidine | % | P-Value |
|-------|-----------------|---------|---|-----------------|---|---------|
| 1     | Cough           | 11      | 52.39 | 3               | 14.28 | 0.008   |
| 2     | Bradycardia     | 0       | 0   | 2               | 9.52  | 0.07    |
| 3     | Hypotension     | 0       | 0   | 4               | 19.04 | 0.035   |
| 4     | Hypertension    | 17      | 80.95 | 2               | 9.52  | <0.001  |
| 5     | Vomiting        | 1       | 4.76 | 0               | 0     | 0.311   |
| 6     | Laryngospasm    | 0       | 0   | 0               | 0     | -       |
| 7     | Bronchospasm    | 0       | 0   | 0               | 0     | -       |
| 8     | Undue sedation  | 0       | 0   | 0               | 0     | -       |
| 9     | Desaturation    | 0       | 0   | 0               | 0     | -       |

Fig. 4: Comparison of MAP (in mm of Hg) between study and control group

All these changes usually resolve soon, and they are tolerated by most of the patients, but may be deleterious in certain patients. The present study was initiated to evaluate the hemodynamic response of dexmedetomidine during extubation, the quality of extubation, the level of postoperative sedation, complication rate, hemodynamic stability, analgesic effects and lack of respiratory depression, along with its relatively shorter half-life. Dexmedetomidine activates vasomotor center receptors in the medulla and decreases the noradrenaline turnover and central sympathetic outflow. This has resulted in the maintenance of regular sympathetic function like blood pressure and heart rate. During extubation, all the hemodynamic parameters like blood pressure, mean arterial pressure and heart rate were significantly stable in the study group than the control group. Our findings are consistent with other studies which proved that intravenous administration of dexmedetomidine stabilizes vascular hemodynamics, offers smooth extubation and a much more easy and comfortable recovery. Anxiolytic and sedation effect of dexmedetomidine are due to the inhibition of sympathetic outflow and stimulation of parasympathetic division from the locus coeruleus in the brainstem. α2 A and α2 C receptor stimulation in locus coeruleus induces sedation. α2 A and α2 C receptors activation in spinal cord alleviates pain transmission due to decreased release of substance P. Reduction in the norepinephrine release from locus coeruleus stimulates the firing of inhibitory neurons like γ-aminobutyric acid system, which in turn causes adequate sedation and anxiolysis. α2 agonist sedation can be easily aroused and patients co-operate during procedures and also respond to the verbal commands. After extubation, patients who were given the drug dexmedetomidine were little drowsy but responded to verbal commands (Ramsay Sedation Scale 3). The time interval between extubation and eye opening was calculated and found to be prolonged in the dexmedetomidine group, when compared to the controls (Table 2). The dexmedetomidine group experienced a better extubation quality score as well because of the fore mentioned reasons. Similar findings were observed in other studies too. Dexmedetomidine activates the imidazoline-prefering receptors, α2 adrenoceptors, or both in the nucleus tractus.
solitarus (ventrolateral part of medulla) lowers the heart rate. Our study results have shown that dexmedetomidine group had significantly higher incidence of hypotension and bradycardia than the control group. Similar results were observed in other studies too. In a study done by Goel et al., there was an equal prevalence in both groups. Lawrence et al. in his study noted that bradycardia occurred only during 1st and 5th minute during extubation.

There was a insignificant difference in occurrence of vomiting between both groups (Table 4) as that of other studies. In our study, occurrence of cough and raised Blood pressure was significantly high in NS only group and bradycardia and hypotension was significantly higher in Dexmedetomidine group. However, few other studies have also found similar results.

Similar study by Guler et al. had also emphasized that desaturation, bronchospasm, respiratory depression, coughing, laryngospasm and undue sedation were not found in any of the two groups (Table 4).

5. Conclusion
Intravenous administration of dexmedetomidine just prior to extubation minimize the hemodynamic responses to it. Postoperatively it offers smooth tracheal extubation and better sedation. Hypotension and bradycardia due to the administration of dexmedetomidine in few cases is treatable. Life threatening complications like bronchospasm, laryngospasm, respiratory depression and undue sedation can be prevented while using the drug during extubation.

6. Source of Funding
Self.

7. Conflict of Interest
Nil.

References
1. Bindu B, Gowd UP, Gorre V, Murthy RR, Laxmi MB, Pasupuleti S. A double blind, randomized, controlled trial to study the effect of dexmedetomidine on hemodynamic responses during tracheal extubation. J Anaesthesiol Clin Pharmacol. 2013;29(2):162–7.

2. Aksu R, Akın A, Bicer C, Esmaogluc A, Tosun Z. Adem Boyaci. Comparison of the Effects of Dexmedetomidine Versus Fentanyl on Airway Reflexes and Hemodynamic Responses to Tracheal Extubation During Rhinoplasty: A Double-Blind, Randomized, Controlled Study. Curr Ther Res. 2009;7(3):209–20.

3. Vankayalapati SD, Ramsali MV, Dumpyala S, Pasupuleti S. Effect of dexmedetomidine on haemodynamic and recovery responses during tracheal extubation: a randomized comparative study. J Evol Med Dent Sci. 2016;5(46):2880–3.

4. Manne GR, Upadhyay MR, Swadia VN. Effects of low dose dexmedetomidine infusion on haemodynamic stress response, sedation and post-operative analgesia requirement in patients undergoing laparoscopic cholecystectomy. Indian J Anaesth. 2014;58(6):726–31.

5. Rani P, Kumar VRH, Ravishankar M, Sivashanmugam T, SriPriya R, Trilogasundary M. Rapid and reliable smooth extubation – Comparison of fentanyl with dexmedetomidine: A randomized, double-blind clinical trial. Anesth Essays Res. 2016;10(3):597–601.

6. Stone DJ. Anesthesia. In: Miller RD, editor. Airway management. Philadelphia: Churchill Livingstone Co. 2000. p. 1414–51.

7. Turan G, Ozgultekin A, Turan C, Dincer E, Yuksel G. Advantageous effects of dexmedetomidine on haemodynamic and recovery responses during extubation for intracranial surgery. Eur J Anaesthesiol. 2008;25(10):816–20.

8. Ramsay MA, Huddleston P, Hamman B, Tai S, Matter G. The patient state index correlates weel with Ramsay Sedation score in ICU patients. Anesthesiology. 2004;101:338.

9. Hartley M, Vaughan RS. Problems associated with tracheal extubation. Br J Anaesth. 1993;71(4):561–8.

10. Ali L, Jagondi S, Jagdish MB. Attenuation of hemodynamic stress response during emergence from general anesthesia: A prospective randomized controlled study comparing fentanyl and dexmedetomidine. J Evol Med Dent Sci. 2014;3(62):1366–96.

11. Goyal S, Bandil M, Bansal RP. The effectiveness of intravenous dexmedetomidine on haemodynamic responses and recovery following tracheal extubation in patients undergoing intracranial surgery. Int J Basic Clin Pharmacol. 2015;4(2):371–5.

12. Goyal S, Bandil M, Bansal RP. The effectiveness of intravenous dexmedetomidine on haemodynamic responses during tracheal extubation in patients undergoing craniotomies. Int J Res Med Sci. 2017;5(8):3626–30.

13. Lawrence CJ, Lange SD. Effects of a single pre-operative dexmedetomidine dose on isoflurane requirements and perioperative haemodynamic stability. Anaesthesia. 1997;52(8):736–45.

14. Karaaslan K, Yilmaz F, Gulcu N, Colak C, Sereflican M, Kocoglu H. Comparison of dexmedetomidine and midazolam for monitored anesthesia care combined with tramadol via patient-controlled analgesia in endoscopic nasal surgery: A prospective, randomized, double-blind, clinical study. Curr Ther Res. 2007;68(2):39–81.

15. Guler G, Akın A, Tosun Z, Eskiatsoglu E, Mizrak A, Boyaci A. Single-dose dexmedetomidine attenuates airway and circulatory reflexes during extubation. Acta Anaesthesiol Scand. 2005;49(8):1088–91.

Author biography
Shabeel Aboobacker C P, Assistant Professor
Shanmjit Kunikkakath, Assistant Professor
Melbin Baby, Assistant Professor
Salman Mohammed Kutty C, Assistant Professor

Cite this article: Aboobacker C P S, Kunikkakath S, Baby M, Kutty C SM. Effect of dexmedetomidine on hemodynamic and recovery responses during tracheal extubation. Indian J Clin Anaesth 2021;8(2):310-315.